It has been shown that inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of developing CVDs in patients with T2D, and the beneficial effect is mediated by inhibiting NLRP3 inflammasome activity.123 The investigators showed that treatment with an SGLT2 inhibitor attenuates the activation of NLRP3 inflammasome and IL-1β production in patients with T2D and high cardiovascular risk by increasing serum β-hydroxybutyrate.123 These results opened a new door for the treatment of T2D and its complications by targeting the SGLT2-NLRP3-IL-1β pathway. This evidence concerns the gene IL1B and type 2 diabetes mellitus.